Atea Pharmaceuticals

Company snapshot

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company working to address unmet medical needs through novel antiviral treatment.

• 37 active pipeline program(s) linked via ClinicalTrials.gov.
• 35 US patent(s) indexed to this assignee profile.
• 37 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Atea Pharmaceuticals. Not investment advice.

• Peer + 0 momentum

  Vertex Pharmaceuticals (Australia)

  TA overlap score 40

• Peer + 0 momentum

  INOVIO Pharmaceuticals

  TA overlap score 29.2

• Peer + 0 momentum

  ENANTA PHARMACEUTICALS

  TA overlap score 26.8

• Peer + 0 momentum

  Arcturus Therapeutics

  TA overlap score 22.6

Recent activity

Latest pipeline, patent, and corporate events for Atea Pharmaceuticals.

1. Jun 8, 2026 Clinical update

   AT-01B-008 — Phase 3

2. Jun 8, 2026 Clinical update

   AT-01B-006 — Phase 1

3. Jun 8, 2026 Clinical update

   Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting — Phase 1

4. Jun 8, 2026 Clinical update

   GHB04L1 — Phase 1

5. Jun 8, 2026 Clinical update

   Ethinyl Estradioll/Levonorgestrel (EE/LNG) — Phase 1

View all clinical trial activity →

• What is Atea Pharmaceuticals?

  Atea Pharmaceuticals is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker AVIR. Primary therapeutic focus areas include COVID-19, Hepatitis C, HEPATITIS C VIRUS CHRONIC INFECTION, Influenza, Human, Dengue Fever. NovaPharmaNews links 37 clinical pr

• Is Atea Pharmaceuticals publicly traded?

  Yes. Atea Pharmaceuticals is listed with ticker AVIR on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Atea Pharmaceuticals develop or market?

  We link 29 drug profile(s) where Atea Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/atea-pharmaceuticals#company-drugs.

• What are the latest developments for Atea Pharmaceuticals?

  In the last 12 months our linked public records show 37 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Atea Pharmaceuticals focus on?

  Atea Pharmaceuticals focuses on COVID-19, Hepatitis C, HEPATITIS C VIRUS CHRONIC INFECTION based on our analysis of their pipeline programs and drug development activities.